Skip to main content

Table 5 Segmented regression analysis on the quarterly number of antihypertensive prescriptions and ACEIs prescription proportion

From: The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

Variables β1(a) β2(b) β3(c)
Health and Social Care Information Centre (HSCIC) data
ACEIs prescription proportion (%) −0.09 (−0.10, −0.70) --- 0.10 (0.09, 0.13)
ACEIs 179422.8 (155964.2, 202881.5) --- −88326.8 (−128278.1,-48375.6)
ARBs 87446.1 (77192.5, 97699.7) --- −52359.4 (−69821.8, −34897.1)
Diuretics --- --- ---
CCBs 121943.8 (106805.8, 137081.8) --- −40240.7 (−66021.5, 14459.9)
BBs 22331.1 (2253.2, 42409.0) --- 61787.6 (27593.9, 95983.2)
“Others” 15605.9 (12056.8, 19154.0) --- −7041.9 (−13085.4, 998.4)
Clinical Practice Research Datalink (CPRD) data
ACEIs prescription proportion (%) −0.04 (−0.6, −0.02) --- 0.04 (0.01, 0.07)
ACEIs 15862.3 (14300.5, 17427.0) --- −14529.7 (−17189.5, −11869.9)
ARBs 6993.5 (6377.5, 7609.4) --- −6167.7 (−7216.6, −5118.6)
Diuretics 6414.9 (5325.2, 7504.5) --- −8312.0 (−10167.6, −6456.2)
CCBs 11960.5 (10917.0, 13003.9) --- −9576.0 (−11353.1, −7798.9)
BBs 1681.0 (948.6, 2413.4) --- −1689.5 (−2936.7, −442.2)
“Others” 1765.0 (1572.7, 2002.3) --- −1924.8 (−2328.9, −1520.6)
  1. Regression coefficients (95 % confidence intervals) for the final model (the most parsimonious models); (a):baseline trend; (b):level change following BCBV policy; (c):trend change following BCBV policy; −-- : Indicates insignificant estimates at 0.05 level, after stepwise backward elimination; ACEIs: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptor blockers; CCBs: Calcium channel blockers; BBs: Beta-blockers